ArticleNature immunology2022
STINGing type I IFN-mediated immunopathology in COVID-19.
Article in Nature immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Anti-interferon armamentarium of human coronaviruses.Cellular and molecular life sciences : CMLS · 2025Review
- COVID-19. Biology, pathophysiology, and immunology: a pathologist view.Pathologica · 2023Review
- Phase-separated nucleocapsid protein of SARS-CoV-2 suppresses cGAS-DNA recognition by disrupting cGAS-G3BP1 complex.Signal transduction and targeted therapy · 2023Article
- Warmer ambient air temperatures reduce nasal turbinate and brain infection, but increase lung inflammation in the K18-hACE2 mouse model of COVID-19.The Science of the total environment · 2023Article
- Innate immune recognition against SARS-CoV-2.Inflammation and regeneration · 2023Review
- The impact of prior SARS-CoV-2 infection on host inflammatory cytokine profiles in patients with TB or other respiratory diseases.Frontiers in immunology · 2023Article
- Cytoplasmic DNAs: Sources, sensing, and roles in the development of lung inflammatory diseases and cancer.Frontiers in immunology · 2023Review
- Surrogate cytokine agonists: promising agents against COVID-19.Signal transduction and targeted therapy · 2022Article
- Molecular Function of cGAS-STING in SARS-CoV-2: A Novel Approach to COVID-19 Treatment.BioMed research international · 2022Review
- Time-course RNA-Seq profiling reveals isoform-level gene expression dynamics of the cGAS-STING pathway.Computational and structural biotechnology journal · 2022Article
- T Cell Extracellular Traps: Tipping the Balance Between Skin Health and Disease.Frontiers in immunology · 2022Review
- Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy.Frontiers in immunology · 2022Review
- Blood transcriptome responses in patients correlate with severity of COVID-19 disease.Frontiers in immunology · 2022Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
35301509What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.